欧林生物股价涨5.59%，华富基金旗下1只基金重仓，持有60万股浮盈赚取79.8万元

Core Viewpoint - Oulin Bio experienced a 5.59% increase in stock price, reaching 25.12 CNY per share, with a trading volume of 113 million CNY and a market capitalization of 10.197 billion CNY as of November 14 [1] Company Overview - Chengdu Oulin Biotechnology Co., Ltd. was established on December 11, 2009, and went public on June 8, 2021. The company specializes in the research, production, and sales of human vaccines [1] - The main revenue composition includes: - 90.99% from adsorbed tetanus vaccine - 4.49% from group A and C meningococcal polysaccharide conjugate vaccine - 3.99% from type b Haemophilus influenzae conjugate vaccine - 0.47% from other supplementary products - 0.07% from refined tetanus toxin raw liquid [1] Fund Holdings - Huafu Fund has a significant holding in Oulin Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 600,000 shares, accounting for 7.56% of the fund's net value, making it the fourth-largest holding [2] - The fund has achieved a year-to-date return of 43.03%, ranking 1679 out of 8140 in its category, and a one-year return of 22.35%, ranking 3346 out of 8056 [2] - The fund manager, Liao Qingyang, has been in position for 4 years and 6 days, with a total fund asset size of 216 million CNY and a best return of 22.13% during his tenure [2]